Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome

Christiaan P Sentner, Irene J Hoogeveen, David A Weinstein, René Santer, Elaine Murphy, Patrick J McKiernan, Ulrike Steuerwald, Nicholas J Beauchamp, Joanna Taybert, Pascal Laforêt, François M Petit, Aurélie Hubert, Philippe Labrune, G Peter A Smit, Terry G J Derks, Christiaan P Sentner, Irene J Hoogeveen, David A Weinstein, René Santer, Elaine Murphy, Patrick J McKiernan, Ulrike Steuerwald, Nicholas J Beauchamp, Joanna Taybert, Pascal Laforêt, François M Petit, Aurélie Hubert, Philippe Labrune, G Peter A Smit, Terry G J Derks

Abstract

Glycogen storage disease type III (GSDIII) is a rare disorder of glycogenolysis due to AGL gene mutations, causing glycogen debranching enzyme deficiency and storage of limited dextrin. Patients with GSDIIIa show involvement of liver and cardiac/skeletal muscle, whereas GSDIIIb patients display only liver symptoms and signs. The International Study on Glycogen Storage Disease (ISGSDIII) is a descriptive retrospective, international, multi-centre cohort study of diagnosis, genotype, management, clinical course and outcome of 175 patients from 147 families (86 % GSDIIIa; 14 % GSDIIIb), with follow-up into adulthood in 91 patients. In total 58 AGL mutations (non-missense mutations were overrepresented and 21 novel mutations were observed) were identified in 76 families. GSDIII patients first presented before the age of 1.5 years, hepatomegaly was the most common presenting clinical sign. Dietary management was very diverse and included frequent meals, uncooked cornstarch and continuous gastric drip feeding. Chronic complications involved the liver (hepatic cirrhosis, adenoma(s), and/or hepatocellular carcinoma in 11 %), heart (cardiac involvement and cardiomyopathy, in 58 % and 15 %, respectively, generally presenting in early childhood), and muscle (pain in 34 %). Type 2 diabetes mellitus was diagnosed in eight out of 91 adult patients (9 %). In adult patients no significant correlation was detected between (non-) missense AGL genotypes and hepatic, cardiac or muscular complications. This study demonstrates heterogeneity in a large cohort of ageing GSDIII patients. An international GSD patient registry is warranted to prospectively define the clinical course, heterogeneity and the effect of different dietary interventions in patients with GSDIII.

Figures

Fig. 1
Fig. 1
AGL mutations in the ISGSDIII-cohort depicted per exon/intron
Fig. 2
Fig. 2
Age range of onset of disease features of GSDIII patients

References

    1. Brambilla A, Mannarino S, Pretese R, Gasperini S, Galimberti C, Parini R. Improvement of cardiomyopathy after high-fat diet in two siblings with glycogen storage disease type III. JIMD Rep. 2014;17:91–95. doi: 10.1007/8904_2014_343.
    1. Dagli AI, Zori RT, McCune H, Ivsic T, Maisenbacher MK, Weinstein DA. Reversal of glycogen storage disease type IIIa-related cardiomyopathy with modification of diet. J Inherit Metab Dis. 2009;32:S103–S106. doi: 10.1007/s10545-009-1088-x.
    1. Dagli A, Sentner CP, Weinstein DA (2010) Glycogen storage disease type III. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP (eds). GeneReviews Seattle: University of Washington, 1993–2016 (Updated 2012 Sep 6; Available from: )
    1. Derks TGJ, Smit GP. Dietary management in glycogen storage disease type III: what is the evidence? J Inherit Metab Dis. 2015;38:545–550. doi: 10.1007/s10545-014-9756-x.
    1. Elpeleg ON. The molecular background of glycogen metabolism disorders. J Pediatr Endocrinol Metab. 1999;12:363–379. doi: 10.1515/JPEM.1999.12.3.363.
    1. Folk CC, Greene HL. Dietary management of type I glycogen storage disease. J Am Diet Assoc. 1984;84(293-8):301.
    1. Goldstein JL, Austin SL, Boyette K, et al. Molecular analysis of the AGL gene: identification of 25 novel mutations and evidence of genetic heterogeneity in patients with glycogen storage disease type III. Genet Med. 2010;12:424–430. doi: 10.1097/GIM.0b013e3181d94eaa.
    1. Hoogeveen IJ, van der Ende RM, van Spronsen FJ, de Boer F, Heiner-Fokkema MR, Derks TG (2015) Normoglycemic ketonemia as biochemical presentation in ketotic glycogen storage disease. JIMD Rep. doi:10.1007/8904_2015_511
    1. Ismail H. Glycogen storage disease type III presenting with secondary diabetes and managed with insulin: a case report. Cases J. 2009;2:6891. doi: 10.4076/1757-1626-2-6891.
    1. Kishnani PS, Boney A, Chen YT. Nutritional deficiencies in a patient with glycogen storage disease type Ib. J Inherit Metab Dis. 1999;22:795–801. doi: 10.1023/A:1005549823146.
    1. Kishnani PS, Austin SL, Arn P, Bali DS, Boney A, Case LE, et al. Glycogen storage disease type III diagnosis and management guidelines. Genet Med. 2010;12:446–463. doi: 10.1097/GIM.0b013e3181e655b6.
    1. Laforêt P, Weinstein DA, Smit GPA. The glycogen storage diseases and related disorders. In: Saudubray J-M, van den Berghe G, Walter JH, editors. Inborn metabolic diseases: diagnosis and treatment. Heidelberg: Springer; 2012. pp. 115–140.
    1. Mayorandan S, Meyer U, Hartmann H, Das AM. Glycogen storage disease type III: modified Atkins diet improves myopathy. Orphanet J Rare Dis. 2014;28:196. doi: 10.1186/s13023-014-0196-3.
    1. Moe PJ, Waaler PE, Garatun-Tjeldsto O. Glycogen storage disease type 3 and diabetes mellitus. Acta Paediatr Scand. 1972;61:483–486. doi: 10.1111/j.1651-2227.1972.tb15869.x.
    1. Oki Y, Okubo M, Tanaka S, Nakanishi K, Kobayashi T, Murase T. Diabetes mellitus secondary to glycogen storage disease type III. Diabet Med. 2000;17:810–812. doi: 10.1046/j.1464-5491.2000.00378.x.
    1. Rake JP, Visser G, Labrune P, Leonard JV, Ullrich K, Smit GP. Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I) Eur J Pediatr. 2002;161 Suppl 1:S20–S34. doi: 10.1007/BF02679990.
    1. Rake JP, Visser G, Huismans D, et al. Bone mineral density in children, adolescents and adults with glycogen storage disease type Ia: a cross-sectional and longitudinal study. J Inherit Metab Dis. 2003;26:371–384. doi: 10.1023/A:1025111220095.
    1. Ramachandran R, Wedatilake Y, Coats C, et al. Pregnancy and its management in women with GSD type III - a single centre experience. J Inherit Metab Dis. 2012;35:245–251. doi: 10.1007/s10545-011-9384-7.
    1. Sentner CP, Caliskan K, Vletter WB, Smit GPA. Heart failure due to severe hypertrophic cardiomyopathy reversed by low calorie, high protein dietary adjustments in a glycogen storage disease type IIIa patient. JIMD Rep. 2012;5:13–16. doi: 10.1007/8904_2011_111.
    1. Sharma RWS. Diabetes in patients with glycogen storage disease types I and III. Diabet Med J Br Diabet Assoc. 2009;26:102.
    1. Shen JJ, Chen YT. Molecular characterization of glycogen storage disease type III. Curr Mol Med. 2002;2:167–175. doi: 10.2174/1566524024605752.
    1. Shen J, Bao Y, Liu HM, Lee PJ, Leonard JV, Chen YT. Mutations in Exon 3 of the glycogen debranching enzyme gene are associated with glycogen storage disease type III that is differentially expressed in liver and muscle. J Clin Invest. 1996;98:352–357. doi: 10.1172/JCI118799.
    1. Spengos K, Michelakakis H, Vontzalidis A, Zouvelou V, Manta P. Diabetes mellitus associated with glycogen storage disease type III. Muscle Nerve. 2009;39:876–877. doi: 10.1002/mus.21201.
    1. Valayannopoulos V, Bajolle F, Arnoux JB, et al. Successful treatment of severe cardiomyopathy in glycogen storage disease type III With D, L-3-hydroxybutyrate, ketogenic and high-protein diet. Pediatr Res. 2011;70:638–641. doi: 10.1203/PDR.0b013e318232154f.
    1. Verbeek RJ, Sentner CP, Smit GP, et al. Muscle ultrasound in patients with glycogen storage disease types I and III. Ultrasound Med Biol. 2015;42:133–142. doi: 10.1016/j.ultrasmedbio.2015.08.013.
    1. Vertilus SM, Austin SL, Foster KS, et al. Echocardiographic manifestations of glycogen storage disease III: increase in wall thickness and left ventricular mass over time. Genet Med. 2010;12:413–423. doi: 10.1097/GIM.0b013e3181e0e979.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться